Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post Marketing Surveillance of Jakavi® (Ruxolitinib) in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea

NCT05621733 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05621733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05621733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post Marketing Surveillance of Jakavi® (Ruxolitinib) in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
April 7, 2023
Completion date
May 8, 2026
Enrollment
140 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

graft-versus-host disease